首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   161596篇
  免费   12857篇
  国内免费   7319篇
耳鼻咽喉   587篇
儿科学   2951篇
妇产科学   1816篇
基础医学   27042篇
口腔科学   2485篇
临床医学   12973篇
内科学   32244篇
皮肤病学   2249篇
神经病学   11354篇
特种医学   2750篇
外国民族医学   29篇
外科学   9382篇
综合类   25399篇
现状与发展   42篇
预防医学   10447篇
眼科学   1554篇
药学   20721篇
  30篇
中国医学   6092篇
肿瘤学   11625篇
  2024年   185篇
  2023年   1711篇
  2022年   2850篇
  2021年   5507篇
  2020年   4767篇
  2019年   4695篇
  2018年   4566篇
  2017年   4920篇
  2016年   5642篇
  2015年   6359篇
  2014年   10245篇
  2013年   11408篇
  2012年   10666篇
  2011年   11661篇
  2010年   9374篇
  2009年   9068篇
  2008年   9238篇
  2007年   8874篇
  2006年   8013篇
  2005年   7215篇
  2004年   5984篇
  2003年   5130篇
  2002年   4050篇
  2001年   3502篇
  2000年   2913篇
  1999年   2495篇
  1998年   2324篇
  1997年   2023篇
  1996年   1685篇
  1995年   1534篇
  1994年   1383篇
  1993年   1144篇
  1992年   1015篇
  1991年   892篇
  1990年   772篇
  1989年   658篇
  1988年   591篇
  1987年   520篇
  1986年   460篇
  1985年   864篇
  1984年   829篇
  1983年   617篇
  1982年   652篇
  1981年   530篇
  1980年   474篇
  1979年   380篇
  1978年   308篇
  1977年   249篇
  1976年   255篇
  1975年   215篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
91.
92.
The hepatitis C virus (HCV) is a pandemic human pathogen posing a substantial health and economic burden in both developing and developed countries. Controlling the spread of HCV through behavioural prevention strategies has met with limited success and vaccine development remains slow. The development of antiviral therapeutic agents has also been challenging, primarily due to the lack of efficient cell culture and animal models for all HCV genotypes, as well as the large genetic diversity between HCV strains. On the other hand, the use of interferon-α-based treatments in combination with the guanosine analogue, ribavirin, achieved limited success, and widespread use of these therapies has been hampered by prevalent side effects. For more than a decade, the HCV RNA-dependent RNA polymerase (RdRp) has been targeted for antiviral development. Direct acting antivirals (DAA) have been identified which bind to one of at least six RdRp inhibitor-binding sites, and are now becoming a mainstay of highly effective and well tolerated antiviral treatment for HCV infection. Here we review the different classes of RdRp inhibitors and their mode of action against HCV. Furthermore, the mechanism of antiviral resistance to each class is described, including naturally occurring resistance-associated variants (RAVs) in different viral strains and genotypes. Finally, we review the impact of these RAVs on treatment outcomes with the newly developed regimens.  相似文献   
93.
目的:研究组蛋白去乙酰化酶1(histone deacetylase 1,HDAC1)和细胞周期蛋白依赖性激酶1(cyclin-dependent kinase 1,CDK1)在结肠癌组织中的表达水平及其与患者临床病理特征及预后的关系。方法:收集2012年2月至2013年6月在本院普外科进行手术切除的51例结肠癌患者的肿瘤组织和癌旁非肿瘤组织,采用qRT-PCR法检测组织中HDAC1和CDK1 mRNA相对表达量,采用免疫组织化学染色法检测HDAC1和CDK1蛋白阳性表达率,分析肿瘤组织中HDAC1和CDK1表达的相关性及其与患者肿瘤直径、淋巴结转移等临床病理特征的关系,采用Kaplan-Meier生存函数分析HDAC1和CDK1不同表达情况与患者5年总生存率的关系。结果:肿瘤组织中HDAC1和CDK1 mRNA表达水平和蛋白阳性表达率均高于癌旁非肿瘤组织(P<0.05);肿瘤组织中HDAC1表达水平与CDK1表达水平呈显著正相关(P=0.012);肿瘤组织中HDAC1表达与患者肿瘤直径和组织分化程度有关(P<0.05),CDK1与肿瘤直径、TNM分期、分化程度、淋巴结转移有关(P<0.05);HDAC1、CDK1阳性表达患者5年总生存率均低于其相应阴性表达患者(P<0.05),HDAC1和CDK1共阳性表达患者5年总生存率低于HDAC1和(或)CDK1阴性患者(P<0.05)。结论:HDAC1和CDK1在结肠癌组织中高表达,与患者不良预后有关且两者呈正相关,推测两者在促进结肠癌进展中可能存在协同作用。  相似文献   
94.
95.
《Vaccine》2020,38(10):2315-2325
In the preparation of glycoconjugate vaccines in clinical practice, two highly immunogenic carrier proteins, CRM197 and tetanus toxoid (TT), are predominantly conjugated with the capsular polysaccharides (CPSs) of bacterial pathogens. In addition, TT has long been used as an effective vaccine to prevent tetanus. While these carrier proteins play an important role in immunogenicity and vaccine design alike, their defined human major histocompatibility complex class II (MHCII) T cell epitopes are inadequately characterized. In this current work, we use mass spectrometry to identify the peptides from these carrier proteins that are naturally processed and presented by human B cells via MHCII pathway. The MHCII-presented peptides are screened for their T cell stimulation using primary CD4+ T cells from four healthy adult donors. These combined methods reveal a subset of eleven CD4+ T cell epitopes that proliferate and stimulate human T cells with diverse MHCII allelic repertoire. Six of these peptides stand out as potential immunodominant epitopes by responding in three or more donors. Additionally, we provide evidence of these natural epitopes eliciting more significant T cell responses in donors than previously published TT peptides selected from T cell epitope screening. This study serves toward understanding carrier protein immune responses and thus enables the use of these peptides in developing novel knowledge-based vaccines to combat persisting problems in glycoconjugate vaccine design.  相似文献   
96.
Increasing numbers of arthroplasties are also accompanied by postoperative infections. The main purpose was to evaluate preoperative serum bilirubin levels between patients with and without infections after shoulder and knee arthroplasties. For this retrospective case-control single-center study, a total of 108 patients were extracted from a prospectively collected database. Eighteen patients with infections after shoulder (n = 8) and knee (n = 10) arthroplasty were matched by age, gender, and implant type in a 1:5-scenario to 90 patients (40 shoulders and 50 knees) without postoperative infection. Demographic data, preoperative blood parameters, and postoperative infection-related outcomes were evaluated. Total bilirubin was the only preoperative parameter significantly different between the infection (8.21 ± 3.25 μmol/L or 0.48 ± 0.19 mg/dL) and noninfection (10.78 ± 4.62 μmol/L or 0.63 ± 0.27 mg/dL; P = .014) group, while C-reactive protein and other liver parameters were similar between the groups. Significantly more controls (92.1%) had preoperative bilirubin levels above 8.72 μmol/L or 0.51 mg/dL than cases (7.9%; P = .007). The 5-year infection survival-rate was 65.6% for patients with preoperative bilirubin levels < 8.72 μmol/L or < 0.51 mg/dL and 91.2% with ≥ 8.72 μmol/L or ≥ 0.51 mg/dL. Mildly decreased preoperative bilirubin levels with a cutoff at 8.72 μmol/L or 0.51 mg/dL were significantly associated to patients with infections after shoulder and knee arthroplasty. There were no differences in other blood parameters or comorbidities between patients with infections and their matched-controls.  相似文献   
97.
98.
目的:观察地黄饮子加减方对血管性痴呆模型大鼠学习记忆能力及海马CA1区神经元的影响。方法:将84只SD雄性大鼠,按随机原则选出12只大鼠作为假手术组,其余72只大鼠采用两血管阻断法制备血管性痴呆模型,筛选60只模型大鼠,每组12只,随机分为模型组,尼莫地平组(0. 011 g·kg~(-1)),地黄饮子加减方高、中、低(4. 54,2. 27,1. 14 g·kg~(-1))剂量组。连续灌胃30 d后,Morris水迷宫检测大鼠学习记忆能力,苏木素-伊红(HE)观察海马CA1区神经元形态结构改变,透射电镜观察海马CA1区神经元超微结构变化,原位细胞凋亡检测法(TUNEL)检测海马CA1区细胞凋亡水平,免疫组化(IHC)检测海马CA1区组织磷脂酰肌醇3-激酶(PI3K),蛋白激酶B(Akt),半胱氨酸蛋白酶-3(Caspase-3)表达水平。结果:与假手术组比较,模型组大鼠逃避潜伏期显著延长,穿越原平台次数显著减少(P 0. 01),海马CA1区神经元形态均有不同程度地损伤,凋亡率显著增加(P 0. 01),PI3K,Akt的积分吸光度和平均积分吸光度明显降低(P 0. 01),Caspase-3的积分吸光度和平均积分吸光度显著增高(P 0. 01);与模型组比较,各给药组大鼠逃避潜伏期缩短(P 0. 05,P 0. 01),穿越原平台次数增加(P 0. 05,P 0. 01),PI3K,Akt的积分吸光度和平均积分吸光度值显著增高(P 0. 01),Caspase-3的积分光密度和平均积分吸光度不同程度降低(P 0. 05,P 0. 01)。结论:地黄饮子加减方可改善血管性痴呆模型大鼠学习记忆能力和海马CA1区神经元损伤,潜在机制可能与PI3K/Akt信号转导途径的激活,抑制大鼠海马CA1区神经细胞的凋亡有关。  相似文献   
99.
《Molecular immunology》2015,63(2):296-304
Regulatory B cells (Bregs) are defined by their ability to restrain inflammatory responses both in vivo and in vitro. Interleukin 10 (IL-10) production by Bregs is thought to be central to their ability to regulate inflammation, largely due to IL-10s’ ability to suppress pro-inflammatory cytokine production by effector lymphocytes and to maintain the differentiation of regulatory T cells (Tregs). However, with an increase in available published data, it has become evident that Bregs utilize a number of suppressive mechanisms in order to alter the activation of a variety of different lymphocytes. Here, we summarize the multiplicity of cellular targets of Breg-mediated suppression and describe the mechanisms employed by Bregs to suppress chronic inflammatory responses.  相似文献   
100.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号